Autocatalytic Activation of the Furin Zymogen Requires Removal of the Emerging Enzyme’s N-Terminus from the Active Site

Katarzyna Gawlik1, Sergey A. Shiryaev1, Wenhong Zhu1, Khatereh Motamedchaboki1, Roxane Desjardins2, Robert Day2, Albert G. Remacle1, Boguslaw Stec1, Alex Y. Strongin1*

1 Burnham Institute for Medical Research, La Jolla, California, United States of America, 2 University of Sherbrooke, Sherbrooke, Quebec, Canada

Abstract

Background: Before furin can act on protein substrates, it must go through an ordered process of activation. Similar to many other proteases, furin is synthesized as a zymogen (profurin) which becomes active only after the autocatalytic removal of its auto-inhibitory prodomain. We hypothesized that to activate profurin its prodomain had to be removed and, in addition, the emerging enzyme’s N-terminus had to be ejected from the catalytic cleft.

Methodology/Principal Findings: We constructed and analyzed the profurin mutants in which the egress of the emerging enzyme’s N-terminus from the catalytic cleft was restricted. Mutants were autocatalytically processed at only the primary cleavage site Arg-Thr-Lys-Arg107 ↓ Asp108, but not at both the primary and the secondary (Arg-Gly-Val-Thr-Lys-Arg75 ↓ Ser76) cleavage sites, yielding, as a result, the full-length prodomain and mature furins commencing from the N-terminal Asp108. These correctly processed furin mutants, however, remained self-inhibited by the constrained N-terminal sequence which continuously occupied the S1 sub-sites of the catalytic cleft and interfered with the functional activity. Further, using the in vitro cleavage of the purified prodomain and the analyses of colon carcinoma LoVo cells with the reconstituted expression of the wild-type and mutant furins, we demonstrated that a three-step autocatalytic processing including the cleavage of the prodomain at the previously unidentified Arg-Leu-Gln-Arg89 ↓ Glu90 site, is required for the efficient activation of furin.

Conclusions/Significance: Collectively, our results show the restrictive role of the enzyme’s N-terminal region in the autocatalytic activation mechanisms. In a conceptual form, our data apply not only to profurin alone but also to a range of self-activated proteases.

Introduction

A variety of proteins, including serine proteases and metalloproteases, growth factors, and adhesion molecules as well as bacterial and viral pathogens, is initially synthesized as inactive precursors. Specific processing is required to transform these preproteins into biologically active proteins [1]. Furin and related proprotein convertases (PCs) are specialized serine endoproteases, which cleave the multibasic motifs RX(R/K)(R/K) to transform preproteins into biologically active proteases and peptides [2]. Seven furin-family proteases (furin, PACE4, PC1/3, PC2, PC4, PC5/6 and PC7) have been identified in humans [3]. Ubiquitously expressed furin is the most studied enzyme among all of the PCs [4,5,6]. Structurally and functionally, furin resembles its evolutionary precursor, yeast kinin. Furin is synthesized as a prepropeptidase which contains a signal peptide, a prodomain, a subtilisin-like catalytic domain, a middle P domain, a cysteine-rich region, a transmembrane anchor and a cytoplasmic tail. The N-terminal 81-residue prodomain (residues Gln27–Arg105) functions as a potent auto-inhibitor [7,8]. Furin and other PCs require proteolytic removal of the inhibitory prodomain to become proteolytically potent enzymes [2,9].

No natural protein inhibitors of furin are known. The highly potent synthetic peptide inhibitor decanoyl-Arg-Val-Lys-Arg-chloromethylketone (dec-RVKR-cmk) and α1-antitrypsin variant Portland are used to inhibit furin in cleavage reactions in vivo and in cell-based tests. The original α1-antitrypsin serpin is the natural inhibitor of neutrophil elastase [10]. After a natural mutation of the active site Met358 to Arg the mutant, called α1-antitrypsin variant Pittsburgh, becomes a potent inhibitor of thrombin [11]. The additional, genetically engineered, mutation at position 355 generates a mutant known as α1-antitrypsin variant Portland (α1-PDX). As a result of this additional mutation, α1-PDX exhibits a minimal furin cleavage motif (Arg355-Ile-Pro-Arg358) in its...
excision at the primary Arg-Thr-Lys-Arg 107

The folded furin zymogen initially undergoes an autocatalytic prodomain. Only a few landmarks of furin activation are known. Synthesized furin occurs through a two-step autoproteolytic mechanism is inactivated and the N-terminus is not released from the proteolytic processing of the furin prodomain. Collectively, our model, the zymogen conformation leading to self-cleavage provides less favorable contacts for all charged residues. The electrostatic forces originating from broken ion bridges provide the energy that would be released as a result of the Arg-Thr-Lys-Arg 107 ↓ Asp 108 site cleavage. This energy burst will stimulate repositioning of the novel N-terminus (Asp 108) and will lead to the mature furin conformation where Asp 108 is 40 Å away from the active site. In the furin zymogen, the egress of the emerging enzyme’s N-terminal region from the active site follows the autocatalytic cleavage of the primary cleavage sequence Arg-Thr-Lys-Arg 107 ↓ Asp 108. To accomplish this egress, the unwinding of the 108–117 region structure is necessary. This unwinding includes a change of the backbone conformation of Lys117, the abrogation of the electrostatic contact of Asp115 with the calcium ion and also with other auxiliary electrostatic contacts and the hydrophobic interactions involving Pro113. It is highly probable that the autocatalytic cleavage at the Arg-Thr-Lys-Arg 107 ↓ Asp 108 site causes Asp115 to become available for electrostatic contact with the calcium ion and, as a result, reposition the backbone to its location observed in active furin. To accommodate the ligation of Asp115 to the calcium ion, the chain reverses direction and ejects the emerging N-terminus thus liberating the multiple S’ sites of the active site of the mature, processed, furin. A similar mechanism was earlier suggested for the maturation of subtilisin BPN’ [27].

According to our modeling, the N-terminal insertions in the mature furin sequence should result in an extended conformation in which the primary cleavage site Arg-Thr-Lys-Arg 107 ↓ Asp 108 will access the active site without breaking the electrostatic interactions of Asp115 with the calcium ion (Figure 1B). Following the cleavage at this primary site, the N-terminal part of the emerging active furin may become partially mobile, albeit incapable of achieving the normally occurring 40 Å repositioning, and, in contrast to wild-type (WT) furin, the N-terminal region 108–117 will continue to occupy the multiple S’ sub-sites of the active site cavity. In turn, in the K117P mutant the steric properties of proline will make any significant repositioning of the N-terminal region nearly impossible, thus making the structure of the 108–117 region in the activated mature furin similar to that of profurin.

Recombinant constructs

To support our modeling studies experimentally and to determine the requirements for the activation of furin, WT and mutant constructs were designed. To obtain the soluble constructs, which could be readily isolated from the medium by metal-chelating chromatography, the human furin sequence was truncated at Ala574 and the truncation was then linked to a flexible 7-residue linker followed by a C-terminal His8 tag. To increase the distance from the N-terminus to the critical Lys117 in the N-terminal region of furin, we constructed the insertion mutants. In the insertion mutants, a single Gly residue and the Gly3 and Gly6 peptide sequences were inserted between positions Pro113 and Thr114 of the furin sequence (G, G3 and G6 mutants, respectively). To confirm that the observed effects were not unique for the Gly-containing sequences, both the positively charged His6 and the negatively charged Asp-Asp-Asp-Lys sequences were also inserted between Pro113 and Thr114 (H6 and D4K mutants, respectively). To determine the role of the hinge motion Lys117,
Figure 1. Structural model of the WT and K117P furins. (A) Stereo view of the WT furin catalytic cleft before (a red ribbon) and after (a blue ribbon) the cleavage at the primary Arg-Thr-Lys-Arg107\textsuperscript{Asp108} site. The red curved arrow indicates the motion of the 108–117 sequence from its position in profurin to its final position in the mature furin enzyme. The open conformation of the mature furin enzyme is stabilized by strong...
electrostatic interactions of Asp115 and a calcium ion (a blue sphere), and, in addition, by two salt bridges (Glu112-Lys135 and Lys117-Glu362). (B) The 26–107 prodomain and the 108–574 catalytic domain-P domain of furin are shown in green and grey, respectively. The modeled structure of the 108–117 sequence in profurin is shown in red while the actual structure of the 108–117 sequence in the mature WT furin enzyme is in blue. Top panels – In the structure of the WT furin, the 76–107 peptide sequence, which is generated as a result of the secondary cleavage, is shown as an orange ribbon. The arrows 1 and 2 indicate the primary and the secondary cleavage sites, respectively. Left panel, profurin; middle panel, mature furin, right panel, close-up. Bottom panels – In the K117P mutant the formation of an additional helix is necessary to eject the emerging N-terminus from the active site but it is sterically forbidden because of the adjacent Pro116. As a result, the N-terminus of the mature mutant enzyme continues to occupy the S’ sub-sites leading to the inactive enzyme. The arrow 1 indicates the cleavage at the primary cleavage site alone that, as a result, generates the liberated intact prodomain (green). Left panel, profurin; middle panel, mature furin, right panel, close-up.

Isolation and the N-terminal sequence of mutant furins

We purified the mutant constructs to identify their N-terminal sequence and enzymatic features. In contrast to the inert D153N mutant, other mutants including the K117P, G, G5, G6, D4K and H6, were readily isolated from the medium using metal-chelating chromatography (Figure 2C). Because the properties of the H6- and G6-furin mutants were very similar, the first will not be discussed in the text below.

To confirm the conversion of profurin into a correctly processed, mature furin, the WT, K117P and G6 purified samples were each subjected to N-terminal microsequencing. Only one N-terminal peptide sequence (D108 VYQEP) that corresponded to the mature furin was identified, thus confirming that the WT and the mutants were processed through an autocatalytic activation pathway involving the cleavage of profurin at the conventional primary Arg-Thr-Lys-Arg107 ↓ Asp108 site [14,15,18,19].

Furin activity assays

The WT construct exhibited a high proteolytic activity against the 1-PDX. A specific inhibitor of furin (dec-RVKR-cmk) fully blocked the proteolysis of PA83 by furin. In contrast to the WT, the insertion mutants demonstrated very low activity against PA83. According to our tests, the mutants were 1,000–10,000-fold less potent against PA83 when compared to the WT enzyme. Based on these results we hypothesized that, after the prodromain excision the mutants remained self-inhibited by the N-terminal region of the mature enzyme which still occupied their active site.

Interactions of furins with 1-PDX

Normally, 1-PDX forms a covalent, SDS- and heat-stable, complex with functionally active furin [13]. To determine if the mutants were able to form a complex with 1-PDX, we co-incubated furins with 1-PDX to generate 1-PDX-furin complexes. The residual furin activity was inhibited using EDTA and SDS, and then by heating the samples at 95°C. The reactions were then analyzed both by SDS-PAGE followed by Coomassie staining and Western blotting with the MON-148 antibody against the catalytic domain of furin. Figure 4A shows that 1-PDX formed a stable complex with the WT furin but not with the mutants.

We next employed ELISA to analyze, in greater detail, the ability of furins to form a complex with 1-PDX (Figure 4B). The wells of a 96-well plate were coated with the purified furins. 1-PDX tagged with a FLAG tag was then added to the wells. The levels of the bound 1-PDX were then measured using the FLAG antibody. We determined that the ability of the mutant constructs to interact with 1-PDX was comparable with that of the WT furin. These data suggested that because the multiple S sub-sites were available in the mutants they were capable of a complex formation with the 1-PDX serpin but because the abnormally positioned N-terminal sequence shielded and incapacitated the S’ sub-sites, the inactive were unable to transform the initial complex association with the serpin into a kinetically trapped SDS-stable complex.

Tryptic proteolysis of the furin constructs

To demonstrate that the N-terminal sequence is buried in the furin’s catalytic cleft of the K117P mutant and exposed in WT furin, we used mild trypsin digestion. We suggested that the N-terminal peptides will be efficiently released by trypsin in WT furin but not in the K117P mutant. In turn, the release of the C-terminal peptides will be equally efficient in the WT and K117P constructs. The tryptic digest of the furin constructs followed by LC-MS/MS and the differential spectral count analysis of the peptides confirmed our suggestion. Thus, the release of the N-terminal D108VYQEP TD PKFPQW YLS GV QR peptide...
Activation of Furin

Figure 2. Constructs and the purification of soluble furin. (A) Furin constructs. The constructs were truncated at position Ala574 and C-terminally linked to a Gly3-Ser-Gly3 linker followed by a His6 tag. To generate insertion mutants, the Gly (G), Gly-Gly-Gly-Gly-Gly (G5), Gly-Gly-Gly-Gly-Gly-Gly (G6), Asp-Asp-Asp-Lys (D4K) and His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-His-Hi...
(preprofurin numbering). In contrast to the expected single cleavage of the 13 kDa tagged prodomain at the Arg-Gly-Val-Thr-Lys-Arg$^{75}$ Ser$^{76}$ that should result in two peptide products [18,19,21], furin proteolysis of the prodomain followed by SDS-PAGE demonstrated the existence of two cleavage sites and the presence of three distinct products with apparent molecular weights of 10 kDa, 5 kDa and 3 kDa in the cleavage reactions. Dec-RVKR-cmk reversed the effect of furin and rescued the prodomain from furin proteolysis. N-terminal sequencing determined that the 5 kDa fragment commenced from Ser$^{76}$ and therefore represented the 76–107 region of the prodomain. The determined N-terminal sequence (EPQVQ) suggested that the 3 kDa fragment represented the 90–107 C-terminal sequence of the prodomain (Figure 7C).

Proteolytic processing of the prodomain in LoVo cells confirms a three-step mechanism

To confirm the importance of the cleavage at the tertiary cleavage site (Arg-Leu-Gln-Arg$^{89}$ Glu$^{90}$) in the autocatalytic processing of profurin, we prepared the full-length WT furin and also the constructs in which the primary (R107G), the secondary (K74G/R75G) and the tertiary (R89G) cleavage sites were each inactivated by mutations. We also constructed the double (R89G/R107G, K74G/R75G/R89G and K74G/R75G/R107G) and the
effect on the elution profile of the K117P mature furin (by Western blotting with the MON-148 antibody against the catalytic domain (K117P furin sample was purified by metal-chelating chromatography. The fractions eluted from the column using 500 mM imidazole were analyzed using the differential peptide spectral count analysis. The yield of the WT peptides was taken as 100%. The data of the spectral count analysis of the selected peptides are summarized in Table S1.

doi:10.1371/journal.pone.0005031.g005

triple (K74G/R75G/R89G/R107G) furin mutants in which two and three cleavage sites, respectively, were inactivated by mutations. In addition, we prepared the full-length inert D153N furin. The constructs were transiently transfected in colon carcinoma LoVo cells. We specifically selected LoVo cells for these studies because of the two frameshift mutations in the furin gene of these cells do not allow them to produce furin [32]. Transiently transfected cells were lysed and the lysates were analyzed by Western blotting using the antibodies against the catalytic domain and the cytoplasmic tail of furin (MON-148 and MON-139, respectively). The WT furin was efficiently activated in LoVo cells and generated the intermediate and the mature enzyme (Figure 7D). The efficiency of self-activation of the R89G mutant in which the tertiary cleavage site (Arg-Leu-Gly-Arg89 Glu90) was inactivated, was significantly reduced compared to that of WT furin. The inert mutant (D153N), the primary (R107G) and the secondary (K74G/R75G) cleavage site mutants as well as the double and triple mutants (K74G/R75G/R89G, K74G/R75G/R107G, R89G/R107G, K74G/R75G/R89G/R107G) were incapable of self-activation and, as a result, only the profurin form was detected in the corresponding cell lysates (Figure 7D). Based on these results, we conclude that the cleavage at the tertiary cleavage site (Arg-Leu-Gly-Arg89 Glu90) and a three-step processing is required for the efficient autocatalytic processing and inactivation of the furin inhibitory prodomain in vivo. We suggest that this extensive, three-step processing helps the emerging furin to escape re-inhibition by the residual levels of the non-covalently associated prodomain.

Figure 5. Mass spectrometry analysis of tryptic peptides. The K117P mutant and WT furin were subjected to a mild tryptic digest (trypsin-furin ratio of 1:100 and 1:1000 w/w, 5 min). The digests were analyzed by LC-MS/MS. The relative yield of the representative N-terminal (D108VYQEDTPKFPQQWYLGTVQR138) and the C-terminal (R107GDLAIHLVSPMGTR315) peptides and the peptide from the central part of the furin sequence (M226LDGEVTDAVEAR238) was determined using the differential peptide spectral count analysis. The yield of the WT peptides was taken as 100%. The data of the spectral count analysis of the selected peptides are summarized in Table S1.

doi:10.1371/journal.pone.0005031.g005

Discussion

To prevent unwanted protein degradation and to enable spatial and temporal regulation of proteolytic activity, proteolytic enzymes are synthesized as latent precursors [9,33]. Proteolytic removal of the activation segment (which is also called the inhibitory prodomain) is required to generate a mature, functionally potent, enzyme. The prodomain size ranges from short peptide sequences to independently folded domains over 100 residues. In the multiple proteinases in which the preformed active site exists in the latent precursor, the prodomain sterically blocks the active site, and thereby prevents binding of substrates. In addition to their inhibitory role, the prodomain regions are frequently important for the folding, stability, and intracellular sorting of the latent precursor. Conversion to an active enzyme is stimulated by a change in pH that results in conversion by an autocatalytic mechanism. The requirement of the autocatalytic mechanism is well established for furin, the ubiquitous proprotein convertase that plays a highly significant role in the proteolytic processing of numerous functionally important proteins and peptides. Similar mechanisms are involved in the self-activation of PCs distinct from furin. The complexity of subcellular trafficking and the role of the associated factors (eg. heparan sulfate proteoglycan) in the regulation of PC activation, however, are not completely understood [34].

Generally, activation of furin requires several steps subsequent to the initial cleavage of its inhibitory N-terminal propeptide. As a result of these cleavages, the propeptide inhibitory activity is

Figure 6. The presence of the residual levels of the intact prodomain in the mutant furin samples. (A) Western blotting of the purified furins. The purified furin samples (2 μg each) were analyzed by Western blotting with the MON-150 antibody against the furin prodomain. (B) The prodomain is separated from the activated K117P furin in the course of performing metal-chelating chromatography in the presence of 1 M NaCl. The K117P furin sample was purified by metal-chelating chromatography. The fractions eluted from the column using 500 mM imidazole were analyzed by Western blotting with the MON-148 antibody against the catalytic domain (upper panel) and with the MON-150 antibody against the prodomain of furin (two bottom panels). The 500 mM imidazole elution buffer did (+NaCl) or did not (-NaCl) contain 1 M NaCl. The presence of 1 mM NaCl had no effect on the elution profile of the K117P mature furin (upper panel). (C) Specific activity of the purified WT and K117P furins against Abz-Arg-Val-Lys-Arg-Gly-Leu-Ala-Tyr(NO2)-Asp-OH. The K117 mutant samples were purified either with or without 1 M NaCl and, therefore, the samples we tested either did or did not contain the residual levels of the prodomain (PRO). (D) The WT furin cleaves the prodomain observed in the G6-furin sample. The G6-furin sample (4 μg) which was purified in the absence of 1 M NaCl and therefore contained the residual amounts of the full-length prodomain, was co-incubated for 1 h at 37°C with purified furin (0.5 μg). The reactions were analyzed by Western blotting with the MON-150 antibody against the furin prodomain.

doi:10.1371/journal.pone.0005031.g006
inactivated and the propeptide cleavage fragments are released from the active site of the emerging active furin enzyme [2,14,15,16,17,18,19,21]. Earlier studies of the furin activation pathway have primarily been focused on processing the N-terminal prodomain thus leaving the structural re-arrangements of the N-terminal region of the emerging enzyme incompletely understood [7,19,21,35]. Because the atomic resolution structures of the catalytic domain of furin and the prodomain of furin-like PC1 are known [22,25,36], we modeled the interactions of the prodomain and the catalytic domain which are characteristic for

Figure 7. Furin proteolysis in trans of its inhibitory prodomain. (A) The recombinant furin prodomain was cloned into the pTrcHis A vector and expressed in E. coli. The sequence of the furin prodomain Gln27-Arg107 is in bold. The cleavage sites are indicated by the arrows. The N-terminal peptide sequence of the prodomain starts from Gly2 because of the cleavage of the initiating Met1 in E. coli. The sequence of the cleavage products determined by N-terminal sequencing is underlined. The numbering used is for intact translated human furin. (B) The recombinant furin prodomain (1.8 µg) was incubated at 37°C for 1 h with furin at a molar ratio of 1:1 or 2:1. The digest samples were analyzed by Tricine gel electrophoresis followed by Coomassie staining. Where indicated, dec-RVKR-cmk (50 µM) was added. The sequence numbering of prodomain and cleavage products identified by MS analysis is shown on the left side. (C) The molecular mass of the intact recombinant furin prodomain and the cleavage products was determined by MALDI-TOF MS. The calculated and measured molecular mass of the peptides is shown in Da. (D) A Western blotting analysis of colon carcinoma LoVo cells transiently transfected with the WT furin (WT), the catalytically inert D153N mutant (D153N) and the furin mutants in which the primary (R107G), the secondary (K74G/R75G) and the tertiary (R89G) cleavage sites were inactivated in the prodomain sequence. The R89G/R107G; K74G/R75G/R89G and K74G/R75G/R107G, and K74G/R75G/R89G/R107G are the mutants in which two and three cleavage sites, respectively, were inactivated by mutations. Mock cells are LoVo cells transfected with the original plasmid. The antibodies to the catalytic domain and to the cytoplasmic tail of furin (MON-148 and MON-139, respectively) were used for Western blotting. To show equal loading, the samples were also analyzed by Western blotting with an α-tubulin antibody (bottom panel).

doi:10.1371/journal.pone.0005031.g007
profurin and the transitions of the structure that follow the autocatalytic processing at the primary Arg-Thr-Lys-Arg<sup>107</sup> ↓ Asp<sup>108</sup> site. It appears from our in silico modeling that the relative position of the N-terminal region of the catalytic domain is distinct in profurin and in mature furin. Following the cleavage at the primary site Arg-Thr-Lys-Arg<sup>107</sup> ↓ Asp<sup>108</sup>, the N-terminal region moves away from its original position in profurin to reach its final position in the mature furin molecule.

According to our modeling, the electrostatic interactions of Asp115 with the calcium ion are especially important for the repositioning of the N-terminal 108–113 region. The electrostatic interactions involving Asp115 and the calcium ion perform like a “loaded spring” and this spring is released after the pro-region cleavage to facilitate re-positioning of the N-terminal region from its original position in the furin zymogen to its final position in the mature, processed furin. Our modeling also suggested that the peptide insertions provide an opportunity for the N-terminal part of the emerging furin to remain largely immobile after the autocatalytic cleavage at Arg-Thr-Lys-Arg<sup>107</sup> ↓ Asp<sup>108</sup> and to continue to occupy the active site cavity in the mutants. As a result, the release mechanism remained inactivated and, we suspect, the mutants remained self-inhibited by the mature furin cation of the N-terminus.

To investigate these suspicions and to elucidate the auto-inhibitory function of the N-terminal region in greater detail, we studied the profurin mutants with the K117P mutation of the hinge motion Lys117 and the one, five and six residue insertions in the profurin mutants with the K117P mutation of the hinge motion Lys117 and the one, five and six residue insertions. The TMB/M and TMB/E substrates were purchased from PEPtech. The LC-MS/MS and the differential peptide spectral count analysis of the tryptic fragments confirmed our suggestion that in the K117P mutant the N-terminal region of the emerging furin enzyme continued to be buried in the furin’s catalytic cleft. As a result, this N-terminal sequence of the mutant was inaccessible to trypsin, especially when compared to WT furin.

Our in vitro cleavage and cell-based studies also identified an autocatalytic cleavage of the prodomain at Arg-Leu-Gln-Arg<sup>109</sup> ↓ Gla<sup>110</sup> that is in addition to the primary (Arg-Thr-Lys-Arg<sup>107</sup> ↓ Asp<sup>108</sup>) and secondary (Arg-Gly-Val-Thr-Lys-Arg<sup>75</sup> ↓ Ser<sup>76</sup>) sites. Based on our results, we now believe that a three-step processing of the auto-inhibitory prodomain is required for its inactivation and for preventing re-inhibition of the emerging furin enzyme by the residual amounts of the non-covalently associated inhibitory prodomain. These results add another level of complexity to the molecular mechanics that are involved in the stepwise autocatalytic processing of the prodomain and imply a role for the auxiliary proteins and associated factors in these mechanisms [34].

Collectively, our results describe the events leading to the activation of furin and shed additional light on the restrictive role which is played by the enzyme’s N-terminal region in the autocatalytic activation mechanisms of this and potentially other self-activated proteases.

**Materials and Methods**

**Materials**

Reagents were purchased from Sigma-Aldrich unless indicated otherwise. The fluorescent substrate pyroglutamic acid-Arg-Thr-Lys-Arg-methyl-coumaryl-7-amide was obtained from Peptides International. The internally quenched fluorogenic peptide substrate Abz-Arg-Val-Lys-Arg-Gly-Leu-Ala-Tyr(NO2)-Asp-OH and the furin inhibitor dec-RVKR-cmk were from Bachem. Anthrax protective antigen-83 (PA83) was purchased from List Biological Laboratories. FLAG-tagged furin inhibitor fold-in-trypsin variant Portland (2l-PDX) was from Affinity BioReagents. Restriction enzymes were from New England Biolabs. SF9 insect cell line (an ovarian cell line from fall armyworm Spodoptera frugiperda), Cellflectin Reagent and a pcDNA 3.1 Directional TOPO Expression Kit were obtained from Invitrogen. The baculovirus transfer vector pAcGP67-A and the BaculoGold Linearized DNA were from BD Biosciences-Pharmingen. The Eugene HD transfection reagent was from Roche Diagnostics. SF9 insect cells were routinely grown in SF-900 II SFM medium supplemented with penicillin-streptomycin (100 units/ml and 100 μg/ml, respectively) and Fungizone/amphotericin B (0.25 μg/ml, Omega). The murine MON-148, MON-150 and MON-139 monoclonal antibodies against the catalytic domain, the prodomain and the cytoplasmic tail of furin, respectively, were from Axxora. The rabbit α-tubulin antibody was from Cell Signaling Technology. The peroxidase-conjugated donkey anti-mouse and anti-rabbit IgG were from Jackson ImmunoResearch Laboratories. The TMB/M and TMB/E substrates were purchased from Chemicon.

**Cloning of human furin and plasmid construction for the baculovirus expression system**

Furin was amplified by PCR from a Marathon-Ready cDNA library (Clontech) with the 5’-ATGGAGCTGAGGCCCTGGT-
TGCG-3' and 5'-CTCATCAGAGGGGCGCTCTGTCG-3' oligonucleotides as direct and reverse primers, respectively. The resulting 2.4 kb cDNA fragment was cloned into the HincII site of the pcDNA3 plasmid and then recloned into the pcDNA3-zeo plasmid pre-digested with HinIII and EcoRI. The furin cDNA was then used as a template for preparing the furin constructs. Soluble furin was truncated at the position Ala574 (numbering starts from the initiation Met-1 of pre-profurin) and then C-terminally tagged with a Glys2-Gly3 linker followed by a His6 tag. The 5'-TGATAGCAGGAGGGCGGTGC-3' and the 5'-AGGGTGTGGGATGATGATGATGGTGACCG-3' oligonucleotides were used as direct and reverse primers, respectively, in the PCR reactions (the His6 tag sequence is underlined and the linker sequence is italicized).

In the primers shown below the mutant positions are underlined. The K117P mutant (furin K117P) was generated by PCR mutagenesis using the 5'-GCCGCGCTCTCAGAAGGAGGCCAGAAGGAACCTT-3' and 5'-GGGACGTGTACCAGGAGCCCACA-3' forward and reverse primers, respectively. The forward primer (furin D4K) with the substitution of the essential active site Asp153 was generated using the 5'-GCCGAAATTGGTTCTCATTGACCGGCTGGATGACGAGGAGG-3' and 5'-GTGGTCTGCGACATGGCAGACCC-3' oligonucleotides as the forward and reverse primers, respectively. The 5'-GGGACGTGTACCAGGAGCCCACA-3' (direct) and the 5'-GGGGACGTGTACCAGGAGCCCACA-3' (reverse) primers were used to obtain the G5 mutant (G5-furin). The 5'-GGGACGTGTACCAGGAGCCCACA-3' (reverse) was used to construct the secondary cleavage site mutant (K74G/R75G). The double and triple mutants (K74G/R75G/R107G; K74G/R75G/R89G; R89G/R107G; K74G/R75G/R89G/R107G) were obtained by routine genetic engineering manipulations. The full-length D153N catalytically inactive furin with the substitution of the essential active site Asp153 was generated using the 5'-GGGACGTGTACCAGGAGCCCACA-3' and 5'-GTGGTCTGCGACATGGCAGACCC-3' forward and reverse primers, respectively. The furin mutant constructs were cloned into the pcDNA 3.1/V5-His-TOPO and their sequences were confirmed by DNA sequencing.

Human colon carcinoma LoVo cells (ATCC) were grown in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine serum. Sub-confluent LoVo cells (5x10^6) were transfected with 3 μl of Fugene HD reagent per 1 μg of DNA. Twenty four h after tranfection, cells were lysed in 50 mM Tris-Cl pH 8.0, supplemented with 1% SDS, 1 mM EDTA, 100 mM NaCl, 1 mM phenylmethyl sulfonylfluoride, and a protease inhibitor cocktail. The lysate samples (5 μg total protein each) were analyzed by Western blotting with the furin antibodies.

**Furin expression and purification**

Sf9 cells were co-transfected with the recombinant pAcGP67-A vectors and the BaculoGold linearized DNA using Cellfectin. The amplification of the recombinant baculovirus and the preparation of a high-titer viral stock were performed in Sf9 cells according to the manufacturer’s instructions (Invitrogen). Cells (2x10^6 cell/ml) infected at a multiplicity of infection 1–2 were then cultured in suspension at 27°C in SF-900 II SFM medium (1 L). After a 36–38 h incubation, the medium was centrifuged at 200 xg and then at 15,000 xg (30 min each; 4°C). The supernatant was concentrated 20-fold using Amicon Ultra 30k-cutoff membrane (Millipore). 1 M Tris-HCl, pH 8.0, was added to the samples to obtain a final concentration of 20 mM. Furin was isolated from the medium samples using Ni2+-chelating chromatography on the HiTrap Chelating HP 1.6x2.5 cm size column (Amersham Biosciences) equilibrated with PBS. After eluting the impurities with 60 ml of a linear gradient of 0–25 mM imidazole, furin was eluted with 500 mM imidazole. Where indicated, 1 M NaCl was included in all of the buffers used for the purification of furin. The purified fractions were pooled, dialyzed against PBS and stored at -80°C. Purified
furan samples were analyzed by SDS-PAGE, Western blotting and enzyme activity assays. The typical yield of purified furin was approximately 1 mg/liter of cell culture medium. Following SDS-PAGE and the transfer of the proteins onto a membrane support, the N-terminal peptide sequence of furin was determined by N-terminal microsequencing at ProSeq (Boxford, MA).

The SDS- and heat-stable complexes of furin with α1-PDX

For the SDS-gel analysis followed by Coomassie staining, α1-PDX (5 μg, 10 μM) was co-incubated for 15 min at ambient temperature with furin (0.5 μg, 1 μM) in either PBS or the SE-900 II SFM medium. For the Western blot analysis, the concentrations of α1-PDX and furin in the reactions were 10-fold less (0.5 μg and 50 ng, respectively). Furin activity was blocked by adding 5 mM EDTA and the 2× SDS-PAGE sample buffer (125 mM Tris-HCl, pH 6.8, 4% SDS, 0.005% Bromophenol Blue, 20 mM DTT and 20% glycerol) to the reactions. The reactions were heated for 5 min at 95°C and then analyzed by SDS-PAGE in a 4–20% acrylamide gradient gel followed by either Coomassie staining or Western blotting of the reaction aliquots with the MON-148 antibody.

ELISA of the furin-α1-PDX complexes

To measure the efficiency of the α1-PDX binding with furin, the wells of a 96-well plate (Nunc) were coated for 16 h at 4°C with purified furin constructs (1 μg/ml in 100 μl PBS). BSA (1 μg/ml 100 μl PBS) was used as a control. The wells were then blocked with 3% BSA in PBS-0.05% Tween 20 for 2 h at the ambient temperature. α1-PDX (50 μg/ml in 100 μl PBS containing 3% BSA and 0.05% Tween 20) was added to the wells and the plates were incubated for 1 h at the ambient temperature. After washing the wells five times with PBS-0.05% Tween 20, the murine FLAG M2 antibody (0.5 μg/ml in 100 μl PBS containing 3% BSA and 0.05% Tween 20) was added to the wells and the plates were incubated 1 h at the ambient temperature. After washing the wells five times with PBS-0.05% Tween 20, the murine FLAG M2 antibody (0.5 μg/ml in 100 μl PBS containing 3% BSA and 0.05% Tween 20) was added to the wells and the plates were incubated 1 h at the ambient temperature. The unbound antibody was removed by washings with PBS-0.05% Tween 20. The peroxidase-conjugated donkey anti-mouse IgG (1:10,000 dilution) was added to the wells for 1 h. Following extensive washing with PBS-0.05% Tween 20 and then with water, a TMB/E substrate was added to the wells. The reaction was stopped by adding 0.1 ml 1 M H₂SO₄. The 450 nm value was measured using a plate reader. The samples were analyzed in triplicate.

Purification of the furin prodomain

The prodomain was prepared using PCR amplification of the full-length furin cDNA. The 5’-CACAGAGGTCTTTGACCAACAGG-3’ and 5’-TCACCCGTATAGTCGCGATTTGCG-3’ oligonucleotides were used as direct and reverse primers, respectively, in the PCR reactions. The amplified fragment contained the prodomain sequence from Gln27 to the Arg-Thr-Lys-Thr-Lys-Pro-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-Lys-Thr-l...
human furin propeptide was docked into the crystal structure of the mouse furin catalytic domain using the DOT program (www.sdcu.edu/CCMS/DOT). To avoid sterically clashes the side chain positions were corrected manually using the Xfit program (www.sdcu.edu/CCMS/Packages/XTALVIEW/xtalview.html). The structure was then energy-minimized using the CHARMM22 force field molecular dynamics software of the Discovery Studio software package (Accelrys, http://www.accelrys.com/products/dstudio). The model was then validated using Molprobity (molprobity.biochem.duke.edu).

References

1. Seidah NG, Mayer G, Zaid A, Rouselet E, Nassoury N, et al. (2008) The activation and physiological functions of the proprotein convertases. Int J Biochem Cell Biol 40: 1111–1125.

2. Thomas G (2002) Furin at the cutting edge: from protein traffic to embryogenesis and disease. Nat Rev Mol Cell Biol 3: 753–766.

3. Fugger M, Day R (2005) Cutting back on pro-protein convertases: the latest approaches to pharmacological inhibition. Trends Pharmacol Sci 26: 294–301.

4. Bassi DE, Fu J, Lopez de Caceres R, Klein-Szanto AJ (2005) Proprotein convertases: “master switches” in the regulation of tumor growth and progression. Mol Carcinog 44: 151–161.

5. Khath AB, Siegfreid G, Chretien M, Metrakos P, Seidah NG (2002) Proprotein convertases in tumor progression and malignancy: novel targets in cancer therapy. Am J Pathol 160: 1921–1935.

6. Scamnafi N, Calvo F, Chretien M, Seidah NG, Khath AM (2006) Proprotein convertases: lessons from knockouts. Fauci J 20: 1954–1963.

7. Fugger M, Limperis PC, Beaulieu-Andy V, Gagnon F, Lavigne P, et al. (2002) Inhibitory potency and specificity of subtilase-like pro-protein convertase (SPC) prodomains. J Biol Chem 277: 7648–7656.

8. Bhattacharya A, Xu P, Wang P, Osborne MJ, Ni F (2007) Conformational analyses of a partially-folded bioactive prodomain of human furin. Biopolymers 86: 329–344.

9. Lazure C (2002) The peptidezyme zymogen proregresions: nature’s way of preventing undesired activation and proteolysis. Curr Pharm Des 8: 511–531.

10. Travis C, Salvesen GS (1993) Human plasma proteinase inhibitors. Annu Rev Biochem 52: 653–709.

11. Lewis JH, Landman BO, Spoto JA, Hasiba U (1978) Antithrombin Pittsburgh: localization to the TGN and recycling from the cell surface. Embo J 13: 18–33.

12. Anderson ED, Thomas L, Hayflick JS, Thomas G (1993) Inhibition of HIV-1 gp160-dependent membrane fusion by a furin-directed alpha 1-antitrypsin variant. J Biol Chem 268: 24087–24091.

13. Jean F, Stella K, Thomas G, Liu G, Xiang Y, et al. (1998) alpha1-Antitrypsin and internal propeptide cleavage. Embo J 17: 1508–1518.

14. Lehre R, Mollov SS, Thorne BA, Thomas G (1992) Activation of human furin precursor processing endoprotease occurs by an intramolecular autoproteolytic cleavage. J Biol Chem 267: 14304–14308.

15. Rehmann A, Duerer AJ, Kaufman RJ (1992) Regulation of PACE propeptide-processing activity: requirement for a post-endoplasmic reticulum compartment and autoproteolytic activity. Proc Natl Acad Sci U SA 89: 8233–8239.

16. Cremers JW, Vey M, Schafer W, Aoyoshi TA, Roebroek AJ, et al. (1995) Endoproteolytic cleavage of its propeptide is a prerequisite for efficient transport of furin out of the endoplasmic reticulum. J Biol Chem 270: 2695–2702.

17. Mollov SS, Thomas L, VanSlyke JK, Stenberg PE, Thomas G (1994) Intracellular trafficking and activation of the furin proprotein convertase: localization to the TGN and recycling from the cell surface. Embo J 13: 18–33.

18. Anderson ED, Mollov SS, Jean F, Fri H, Shimamura S, et al. (2002) The ordered and compartment-specific autoproteolytic removal of the furin intramolecular chaperone is required for enzyme activation. J Biol Chem 277: 12079–12089.

19. Anderson ED, VanSlyke JK, Thulin CD, Jean F, Thomas G (1997) Activation of the furin endopeptidase is a multiple-step process: requirements for acidification and internal propeptide cleavage. Embo J 16: 1508–1518.

20. Brossette L, Charet G, Lengue JM, Lavigne P, Lehre R (2004) Identification of furin pro-region determinants involved in folding and activation. Biochem J 379: 757–763.

21. Feliciani SF, Thomas L, Scott GK, Subbian E, Hung CH, et al. (2006) Identification of a pH sensor in the furin propeptide that regulates enzyme activation. J Biol Chem 281: 16108–16116.

22. Heinrich S, Lindberg I, Bode W, Than ME (2005) Proprotein convertase models based on the crystal structures of furin and kexin: explanation of their specificity. J Mol Biol 345: 211–227.

23. Siezen RJ, Leunissen JA (1997) Subtilases: the superfamily of subtilisin-like serine proteases. Protein Sci 6: 501–523.

24. Siezen RJ, Leunissen JM, S U (1995) Homology analysis of the propeptides of subtilisin-like serine proteases (subtilases). Intramolecular chaperones and protein folding (eds U Shinde and M Inouye). pp 233–265.

25. Heinrich S, Cameron A, Bourcen GV, Kiefersr B, Huber R, et al. (2003) The crystal structure of the proprotein processing proenzymatic furin explains its stringent specificity. Nat Struct Biol 10: 520–526.

26. Rockwell NC, Thoener JW (2004) The fastest cuts of all: crystal structures of Kex2 and furin reveal secrets of precursor processing. Trends Biochem Sci 29: 80–87.

27. Gallagher T, Gilliland G, Wang L, Bryan P (1995) The prosegment-subtilisin BPN’ complex: crystal structure of a specific ‘foldase’. Structure 3: 907–914.

28. Remacle AG, Shyaraev A, Oh ES, Cielpak P, Srinivasan A, et al. (2008) Substrate cleavage analysis of furin and related proprotein convertases. A comparative study. J Biol Chem 283: 20897–20906.

29. Young JA, Collier RJ (2007) Anthrax toxin: receptor binding, internalization, pore formation, and translocation. Annu Rev Biochem 76: 243–265.

30. Petsa G, Collier RJ, Klippen KR, Leppla SH, Liddington RC (1997) Crystal structure of the anthrax toxin protective antigen. Nature 385: 833–838.

31. Mollov SS, Bresnahan PA, Leppla SH, Klippen KR, Thomas G (1992) Human furin is a calcium-dependent serine endoprotease that recognizes the sequence Arg-X-X-Arg and efficiently cleaves anthrax toxin protective antigen. J Biol Chem 267: 16396–16402.

32. Takahashi S, Nakagawa T, Kashi K, Banno T, Duguay SJ, et al. (1995) A second mutant allele of furin in the processing-incompetent cell line, LeVo. Evidence for involvement of the hom B domain in autocatalytic activation. J Biol Chem 270: 26565–26569.

33. Lopez-Otin C, Bond JS (2008) Proteases: Multifunctional enzymes in life and disease. J Biol Chem.

34. Harper M, Hanlin J, Asselin MC, Marcinkiewicz E, et al. (2008) The regulated cell surface zymogen activation of the proprotein convertase PC5A directs the processing of its secretory substrates. J Biol Chem 283: 2373–2384.

35. Mollov SS, Anderson ED, Jean F, Thomas G (1999) Bicycling the furin pathway: from TGN localization to pathogen activation and embryogenesis. Trends Cell Biol 9: 28–35.

36. Langrea MA, Bryan PN, Sari N, Orban J (2002) Solution structure of the pro-hormone convertase 1 pro-domain from Mus musculus. J Mol Biol 320: 801–812.

37. Liu H, Sadygov RG, Yates JR 3rd (2004) A model for random sampling and estimation of relative protein abundance in shotgun proteomics. Anal Chem 76: 801–812.

38. Zybailov B, Coleman MK, Florens L, Washburn MP (2005) Correlation of stable isotope labeling. Anal Chem 77: 6218–6224.

Supporting Information

Table S1

| Found at: doi:10.1371/journal.pone.0005031.s001 (0.05 MB DOC) |

Author Contributions

Conceived and designed the experiments: KG AYS. Performed the experiments: KG SS WZ KM AR. Analyzed the data: KG SS WZ KM BS AYS. Contributed reagents/materials/analysis tools: RD RD BS. Wrote the paper: AYS.